Phase II Study of First-line Capecitabine Plus Oxaliplatin Plus Aflibercept for 6 Cycles Followed by Capecitabine Plus Aflibercept as Maintenance Therapy in Patients With Metastatic Colorectal Cancer: DROP and GO Trial
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2014
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms Drop and Go
- Sponsors Sanofi
- 21 Nov 2014 Last checked against ClinicalTrials.gov record.
- 17 Nov 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 20 Mar 2014 New trial record